FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma
It also approved the Oncomine Dx Target Test as a companion diagnostic device to aid in patient selection
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy in Patients with Metastatic or Recurrent Cancer
Findings from an assessment of the utility of broad germline panel testing in a prospective pan-cancer cohort
Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from Conventional Histopathological Slides
When aided by a deep learning model, pathologists make faster and more accurate diagnoses of soft tissue sarcomas
Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced Gastric/GEJ Cancer
Findings from a post hoc KEYNOTE-061 study analysis in second-line treatment for gastric/gastro-oesophageal junction adenocarcinoma
FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study
TILs Therapy Shows Promise in the Management of Anti-PD-1-Resistant Metastatic NSCLC
The results from a phase I study with tumour-infiltrating lymphocytes infusion in patients with metastatic non-small cell lung cancer
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients
Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients with SCLC
Findings from a phase III study of hippocampal avoidance during prophylactic cranial irradiation in patients with small-cell lung cancer
Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced NSCLC
Study findings point to potential to integrate prior antibiotic exposure in decision-making process for first-line treatment of advanced non-small cell lung cancer
FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease
Hypoxia-inducible factor inhibitor was investigated in the ongoing Study 004
A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical Utility in NETs Management
The 51-gene expression-based liquid biopsy accurately diagnoses neuroendocrine tumours and is an effective surrogate marker compared to chromogranin A
FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma
Evidence for efficacy of combination treatment is based the results of the CLEAR study